Finance

Beta
Lists
4DN:FRA
Denali Therapeutics Inc
€17.02
+0.35%
(+0.060) 1D
Jun 8, 10:16:45 AM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 4DN...
Open
€16.60
High
€17.02
Low
€16.36
Mkt. cap
3.10B
Avg. vol.
16.00
Volume
1.23K
52-wk high
€19.24
52-wk low
€10.78
No. of employees
507
Open
€16.60
High
€17.02
Low
€16.36
Mkt. cap
3.10B
Avg. vol.
16.00
Volume
1.23K
52-wk high
€19.24
52-wk low
€10.78
No. of employees
507
News stories
From sources across the web
About Denali Therapeutics Inc
CEO-
Employees507
Founded2013
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitedenalitherapeutics.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
102.70M
101.95M
97.90M
103.85M
Cost of revenue
102.70M
101.95M
97.90M
103.85M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
32.27M
35.48M
39.46M
33.51M
Operating expense
32.27M
35.48M
39.46M
33.51M
Total operating expenses
134.96M
137.43M
137.36M
137.36M
Operating income
-134.96M
-137.43M
-137.36M
-137.36M
Other non operating income
-
-
-
-
EBT including unusual items
-124.12M
-126.90M
-128.45M
-128.45M
EBT excluding unusual items
-124.12M
-126.90M
-130.09M
-129.71M
Income tax expense
-
-
102.00K
-
Effective tax rate
-
-
-0.08%
-
Other operating expenses
-
-
-
-
Net income
-124.12M
-126.90M
-128.55M
-128.45M
Net profit margin
-
-
-
-
Earnings per share
-0.72
-0.74
-0.73
-0.69
Interest and investment income
11.04M
10.73M
7.28M
7.83M
Interest expense
-200.00K
-200.00K
-
-179.00K
Net interest expenses
10.84M
10.53M
7.28M
7.65M
Depreciation and amortization charges
-
-
-
-
EBITDA
-131.01M
-133.57M
-133.58M
-133.60M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer